RxDoctor Payments Data

David Smith, MD

Cardiovascular Disease · Doylestown, PANPI 1659370104

Payments from drug & device makers

$3,363in general payments, 2019–2025

Across 199 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$701
  • Amgen$390
  • Johnson & Johnson$355
  • Merck$255
  • Pfizer$255
  • Kiniksa Pharmaceuticals International, PLC$220
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,363 in reported general payments places this provider in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$264,705
Medicare patients
1,564
Services billed
4,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban747$917,247
JardianceEmpagliflozin162$200,309
XareltoRivaroxaban163$195,954
Repatha SureclickEvolocumab131$171,792
EntrestoSacubitril/Valsartan114$114,588
Praluent PenAlirocumab26$35,893
FarxigaDapagliflozin Propanediol17$15,520
Atorvastatin Calcium938$14,918
Ezetimibe432$12,104
Digoxin77$10,880
Metoprolol Succinate657$10,446
Valsartan239$9,380
Nebivolol Hcl140$9,209
Amiodarone Hcl141$8,464
Rosuvastatin Calcium472$7,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$255$917,247747 claims
Boehringer IngelheimJardiance$110$200,309162 claims
Johnson & JohnsonXarelto$355$195,954163 claims
NovartisEntresto$701$114,588114 claims
AstraZenecaFarxiga$22$15,52017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →